Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19433685 | 0.73 | PTPN2 (0.39) | NOTUMSTSKDRCHEK1AURKA | |
| SCHEMBL28406622 | 0.69 | KDM4E (0.35) | NOTUMPNMTF2KDRCHEK1 | |
| SCHEMBL10712969 | 0.64 | CA1 (0.32) | CA1CA9STSTSHR | |
| Benzamide SCHEMBL27673932 | 0.64 | HSD17B10 (0.44) | MAPK8TSHR | |
| SCHEMBL30441163 | 0.63 | PNMT (0.46) | NOTUMPNMTF2KDRCHEK1 | |
| SCHEMBL3651831 | 0.63 | PNMT (0.40) | NOTUMPNMTF2KDRCHEK1 | |
| SCHEMBL30387165 | 0.63 | TSHR (0.53) | STSCHEK1TSHR | |
| SCHEMBL30444192 | 0.63 | PNMT (0.40) | NOTUMPNMTF2KDRCHEK1 | |
| SCHEMBL6649922 | 0.63 | STS (0.54) | STSTSHR | |
| SCHEMBL786065 | 0.63 | TSHR (0.53) | STSCHEK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152227-A1 | DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2009126844-A2 | DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2009-10-15 | — | — | WO | claimed |
| US-20140271922-A1 | PIRENZEPINE AS AN AGENT IN CANCER TREATMENT | PROTEOSYS AG (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-2231152-B1 | THIENOPYRANONES AS KINASE INHIBITORS | SIGNALRX PHARMACEUTICALS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8466144-B2 | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents | PROTEOSYS AG (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20110294791-A1 | PIRENZEPINE AS AN AGENT IN CANCER TREATMENT | PROTEOSYS AG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2387405-A2 | PIRENZEPINE AS AN AGENT IN CANCER TREATMENT | ProteoSys AG (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263574-A1 | PIRENZEPINE AS OTOPROTECTIVE AGENT | PROTEOSYS AG (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2379080-A1 | PIRENZEPINE AS OTOPROTECTIVE AGENT | ProteoSys AG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-8039464-B2 | Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases | PROTEOSYS AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-8042008-B2 | Information processing device, transfer circuit and error controlling method for information processing device | FUJITSU LIMITED (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-6486163-B1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-11-26 | — | — | US | disclosed |
| US-6486163-B1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-11-26 | — | — | US | disclosed |
| US-6387909-B1 | VISION DEFECTS; BENIGN PROSTATIC HYPERPLASIA | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-05-14 | — | — | US | disclosed |
| US-6387909-B1 | VISION DEFECTS; BENIGN PROSTATIC HYPERPLASIA | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-05-14 | — | — | US | disclosed |
| EP-1200445-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-05-02 | — | — | EP | disclosed |
| US-6306861-B1 | ANTISPASMODIC AGENTS AND TREATMENT OF INCONSTANCE | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-23 | — | — | US | disclosed |
| WO-2001009140-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271922-A1 | PIRENZEPINE AS AN AGENT IN CANCER TREATMENT | PDK2, PARP1, PDK4 | NOTUM 3088/4885PNMT 150/4885F2 2649/4885 |
| US-20110263574-A1 | PIRENZEPINE AS OTOPROTECTIVE AGENT | PIR, HTR5A, GRIK5 | NOTUM 3159/4885PNMT 63/4885F2 1950/4885 |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | ADRA1D, ADRB3, OPRD1 | NOTUM 2942/4885PNMT 426/4885F2 1032/4885 |
| US-20110294791-A1 | PIRENZEPINE AS AN AGENT IN CANCER TREATMENT | PDK2, PARP1, PDK4 | NOTUM 2927/4885PNMT 141/4885F2 2592/4885 |
| US-20110152227-A1 | DEUTERIUM LABELLED DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF | ADRB3, CHRM3, QDPR | NOTUM 1723/4885PNMT 28/4885F2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.